Intravitreal administration of bevacizumab: Pros and cons

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Dashti Khavidaki, Simin ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; COUNTERFEIT DRUG; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOPHTHALMITIS; EYE INFLAMMATION; GLIOBLASTOMA; GOOD MANUFACTURING PRACTICE; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE ABNORMALITY; KIDNEY CARCINOMA; LOW LEVEL LASER THERAPY; METASTATIC COLORECTAL CANCER; MICROBIAL CONTAMINATION; NON SMALL CELL LUNG CANCER; OFF LABEL DRUG USE; OVARY CANCER; QUALITY CONTROL; RETINA DETACHMENT; RETINA TEAR; RETROLENTAL FIBROPLASIA; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; UTERINE TUBE DISEASE; VISUAL IMPAIRMENT; WET MACULAR DEGENERATION; DRUG FORMULATION; DRUG STABILITY; INTRAVITREAL DRUG ADMINISTRATION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; INTRAVITREAL INJECTIONS;

EID: 84928473510     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-015-0110-0     Document Type: Editorial

References (29)

1. Lexicomp. http://www.lexi.com/.
2. Ng DS, Kwok AK, Chan CW, Li WW. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients. Hong Kong Med J. 2012;18:488-95.
3. The Comparison of Age-related Macular Degeneration Treatment Trial (CATT) Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908. doi:10.1056/NEJMoa1102673.
4. The Comparison of Age-related Macular Degeneration Treatment Trial (CATT) Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.two-year results. Ophthalmology. 2012;119:1388-98. doi:10.1016/j.ophtha.2012.03.053.
5. Meredith TA, McCannel CA, Barr C, Doft BH, Peskin E, Maguire MG, et al. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatment trial (CATT). Ophthalmology. 2015;122:817-21. doi:10.1016/j.ophtha.2014.10.027.
6. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year finding of the IVAN randomized clinical trial. Lancet. 2013;382:1258-67. doi: 10.1016/S0140-6736(13)61501-9.
7. Kodjikian L, Souied EH, Mimoum G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300-9. doi:10.1016/j.ophtha.2013.06.020.
8. Hashemi S, Faramarzi MA, Ghasemi Falavarjani K, Abdollahi M. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. Expert Opin Biol Ther. 2014;14:1837-48. doi:10.1517/14712598.2014.96721.
9. Quiroz-Mercado H. Our experience after 1765 intravitrealinjections of bevacizumab: the importanceof being part of a developing story. Semin Ophthalmol. 2007;22:109-25. doi:10.1080/08820530701420082.
10. Mintz-Hittner HA, Kennedy KA, Chuang AZ, for the BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. New Engl J Med. 2011;364:603-15. doi:10.1056/NEJMoa1007374.
11. Arevalo JF, Sanchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, et al. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: The 2010 GLADAOF lecture. J Ophthalmol. 2011;2011:584238. doi:10.1155/2011/584238.
12. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787-94. doi:10.1038/eye.2013.107.
13. Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A, et al. The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open. 2014;4:e005244. doi:1.1136/bmjopen-2014-005244.
14. Falavarjani KG, Moddarres M, Hashemi M, Parvaresh MM, Naseripour M, Zare-Moghaddam A, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina. 2013;33:971-4.
15. Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol; 2013.
16. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23:2187-93. doi:10.1038/eye.2009.7.
17. Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otain A, Tamuara H, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30:485-90. doi:10.1097/IAE.0b013c3181bd2d51.
18. Lee SH, Woo SJ, Park KH, Kim JH, Song JH, Park KU, et al. Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab. Eye (Lond). 2010;24:226-32. doi:10.1038/eye.2009.86.
19. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-7.
20. Goldberg RA, Flynn Jr HW, Isom R, Miller D, Gonzalez S. An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153:204-8. doi:10.1016/j/ajo.2011.11.035.
21. Chen YH, Wu PC, Shiea J, Lo LH, Wu YC, Kuo HK. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. J Ocul Pharmacol Ther. 2009;25:65-9. doi:10.1089/jop2008.0043.
22. Ornek K, Karahan ZC, Ergin A, Tekeli A, Tekeli O. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother. 2008;42:1425-8. doi:10.1345/aph.1L270.
23. Sheth NK, Post GT, Wisniewski TR, Uttech BV. Multidose vials versus single-dose vials: a study in sterility and cost effectiveness. J Clin Microbiol. 1983;17:377-9.
24. Christensen EA, Mordhorst CH, Jepsen OB. Assessment of risk of microbial contamination by use of multidose containers of injectable products. J Hosp Infect. 1992;20:301-4.
25. Yannuzzi NA, Klufas MA, Quach L, Beatty LM, Kaminsky SM, Crystal RG, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015;133:32-9. doi:10.1001/jamaophthalmol.2014.3591.
26. Trissel LA, Gentempo JA, Anderson RW, Lajeunesse JD. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk level compounding. Am J Health Syst Pharm. 2005;62:285-8.
27. Mackey TK, Cuomo R, Guerra C, Liang BA. After counterfeit avastin®-What have we learned and what can be done. Nat Rev Clin Oncol. 2015; doi:10.1038/nrclinonc.2015.35.
28. Cheng JW, Wei RL. Ranibizumab for age-related macular degeneration. N Engl J Med. 2011;364:582. doi:10.1056/NEJMc1013316#SA2.
29. Sun X, Xun X, Zhang X. Counterfeit bevacizumab and endophthalmitis. N Engl J Med. 2011;365:378-9. doi:10.1056/NEJMc1106415#SA1.